SightGlass Vision’s 18-Month Data on DOT Spectacles Proves Myopia Efficacy

Share

Tweet

Share

Share

Email

SightGlass Vision is set to present its 18-month data the 2025 Academy Meeting in Boston. 

October 6, 2025

DALLAS — SightGlass Vision announced that the latest 18-month data on its Diffusion Optics Technology (DOT 0.2) spectacle lenses confirm myopia efficacy.

The data showed that more than half of children wearing DOT spectacle lenses experienced no clinically meaningful myopia progression—nearly four times the rate seen in children wearing standard single-vision spectacle lenses.¹ These findings further strengthen the growing body of evidence behind contrast management, which powers the company’s unique Diffusion Optics Technology myopia control solution by softly scattering light before it hits the retina.²

The Study Results

The new update will be presented by Jennifer Hill on Oct. 9. The paper is titled “Control of myopia using contrast modulation spectacle lenses in a Chinese population: 18-month results.” It shares interim findings from SightGlass Vision’s ongoing study involving patients across five Chinese hospitals. Building on earlier 12-month results, which showed that SightGlass Vision’s DOT 0.2 can slow average myopia progression by up to 75% after 12 months of wear across diverse populations,³ the 18-month data found that 57% of children wearing DOT lenses had no clinically meaningful myopia progression at all, compared to just 15% in the control group.¹ These results also show significant effects on axial length elongation and cycloplegic spherical equivalent refraction progression, with DOT lens wearers exhibiting 0.34 mm and 0.70D less than the control group, respectively.¹

“We are presenting compelling research at Academy ’25 that reinforces the efficacy of DOT lenses,” said Andrew Sedgwick, CEO of SightGlass Vision. “Momentum continues to grow, with over one million children having worn DOT lenses, and we recently expanded into the U.K. through an early access launch. DOT is becoming a globally trusted solution for protecting children’s vision, and we are grateful for the opportunity to share new insights with our colleagues and to drive more progress in the urgent fight against childhood myopia.”

New Research at Academy 2025

Dr. Debbie Laughton will also be presenting new insights into the relationship between DOT lenses and astigmatism. Twelve-month results from a study of North American children and a study of Chinese children showed that DOT lenses slowed myopic progression but provided no evidence to suggest that the lenses caused an increase in astigmatism.⁵ The proportion of children with astigmatism changed from 87% to 92% in the North American study and from 91% to 88% in the Chinese study after 12-months of wear, with no difference between the control group and the DOT lens wearers.⁵ Additional research into subfoveal choroidal thickening with contrast-, defocus-modulating, and standard single vision lenses will also be presented.

Drs. Debbie Jones, Jill Woods, and Ashley Tucker will present a podium education session developed in association with SightGlass Vision on Oct. 9 at 1:30 p.m. in Room 205 ABC, comparing research on different designs of spectacle lenses for myopia management and offering clinical tips. All other research sessions from SightGlass Vision will be in the Exhibit Hall between 4:30 and 6:30 p.m. on Oct. 9.

Global Reach

SightGlass Vision’s patent-protected DOT lenses have made their commercial debut in several markets, including China, the Netherlands, Israel, Canada, Spain, and the U.K., with over one million children having already worn the lenses.*† Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International.

For more information, visit SightGlassVision.com.

 

*This figure is based on sales data and reflects global usage across multiple regions.

 ^†SightGlass Vision Diffusion Optics Technology spectacle lenses are not available for sale in the United States.

 

References